Active substanceFluconazoleFluconazole
Similar drugsTo uncover
  • Vero-Fluconazole
    capsules inwards 
    VEROPHARM SA     Russia
  • Disorel-Sanovel
    capsules inwards 
  • Diflazon®
    solution d / infusion 
  • Diflucan®
    powder inwards 
    Pfizer Inc.     USA
  • Diflucan®
    capsules inwards 
    Pfizer Inc.     USA
  • Diflucan®
    solution in / in 
    Pfizer Inc.     USA
  • Micon
    solution d / infusion 
  • Medoflucon®
    capsules inwards 
    MEDSERV, LLC     Russia
  • Mycomomax®
    capsules inwards 
    Zentiva c.s.     Czech Republic
  • Mycosyst®
    capsules inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Mycosyst®
    solution d / infusion 
    GEDEON RICHTER, OJSC     Hungary
  • Mycoflucan®
    pills inwards 
  • Mycoflucan®
    solution d / infusion 
  • Nofung®
    capsules inwards 
  • Procanazole
    capsules inwards 
  • Fangifflu
    capsules inwards 
  • Flukozan
    solution d / infusion 
    LENS-PHARM, LLC     Russia
  • Flukoside
    capsules inwards 
  • Flukomabol®
    solution d / infusion 
    PREBAND PFC, LLC     Russia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    capsules inwards 
    PHARMACY 36.6, CJSC     Russia
  • Fluconazole
    solution d / infusion 
  • Fluconazole
    capsules inwards 
  • Fluconazole
    solution d / infusion 
    RUSYUROFARM, LLC     Russia
  • Fluconazole
    capsules inwards 
    VALENTA PHARM, PAO     Russia
  • Fluconazole
    capsules inwards 
    REPLEK FARM Skopje, OOO     Macedonia
  • Fluconazole
    capsules inwards 
    FARMPROJECT, CJSC     Russia
  • Fluconazole
    solution d / infusion 
    EAST-FARM, CJSC     Russia
  • Fluconazole
    capsules inwards 
    OZONE, LLC     Russia
  • Fluconazole
    capsules inwards 
    BIOKOM, CJSC     Russia
  • Fluconazole
    capsules inwards 
    VERTEKS, AO     Russia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    pills inwards 
    TECHNOLOG, JSC     Ukraine
  • Fluconazole
    capsules inwards 
    Hemofarm AD     Serbia
  • Fluconazole
    capsules inwards 
  • Fluconazole
    capsules inwards 
    Astrafarm, CJSC     Russia
  • Fluconazole
    capsules inwards 
    MEDISORB, CJSC     Russia
  • Fluconazole OBL
    capsules inwards 
  • Fluconazole Zentiva
    solution d / infusion 
    Zentiva c.s.     Czech Republic
  • Fluconazole Cabi
    solution d / infusion 
  • Fluconazole STADA
    capsules inwards 
  • Fluconazole-Acti
    solution d / infusion 
    Aktifarm, OOO     Russia
  • Fluconazole-Sandoz®
    capsules inwards 
    Sandoz d.     Slovenia
  • Fluconazole-Teva
    capsules inwards 
  • Flukonorm
    capsules inwards 
  • Flucorus®
    solution d / infusion 
    MS-VITA, LLC     Russia
  • Flukorem
    gel externally 
    REMEDIYA, LLC     Russia
  • Flucostat®
    solution d / infusion 
  • Flucostat®
    capsules inwards 
  • Forkan®
    solution d / infusion 
    Cipla Ltd.     India
  • Forkan®
    capsules inwards 
    Cipla Ltd.     India
  • Ciscan®
    capsules inwards 
  • Dosage form: & nbspcapsules
    Composition:
    Active substance: fluconazole 150 mg.
    Auxiliary substances: lactose monohydrate, starch
    pregelated, magnesium stearate, silicon dioxide colloid, sodium lauryl sulfate.
    Capsule composition:
    Case: gelatin, titanium dioxide.
    Cap: gelatin, titanium dioxide, dye patented blue.The composition of black ink:% W / W: Shellac glossy - 59,420, Iron oxide black - 24,650, N-butyl alcohol - 9,750, Purified water - 3,250, Propylene glycol - 1,300, Industrial methylated alcohol 1,080, Isopropyl alcohol 0,550.

    Description:Hard gelatin capsules number 1, body - white, the lid - light blue with the inscription of black color Z-09 and 150 mg. Contents of capsules: white or almost white powder
    Pharmacotherapeutic group:Antifungal agent.
    ATX: & nbsp

    J.02.A.C   Triazole derivatives

    J.02.A.C.01   Fluconazole

    Pharmacodynamics:
    Fluconazole, a representative of the class of triazole antifungal agents, is a potent selective inhibitor of the synthesis of sterols in the fungal cell.
    The drug is effective in opportunistic fungal infections, incl. caused by Candida spp., Cryptococcus neoformans, Microsporum spp., Trichophyton spp. Also shown is the activity of fluconazole in endemic mycosis models, including infections caused by Blastomyces dermatitidis, Coccidiodes immitis and Histoplasma capsulatum.

    Pharmacokinetics:
    After oral administration fluconazole it is well absorbed, its bioavailability is 90%. The maximum concentration after ingestion, fasting 150 mg is 90% of the plasma content when administered intravenously at a dose of 2.5 - 3.5 mg / l. Simultaneous food intake does not affect the absorption of the drug taken internally.The concentration in the plasma reaches a peak after 0.5-1.5 hours after administration, the half-life of fluconazole is about 30 hours. The plasma concentrations are in direct proportion to the dose. 90% level of equilibrium concentration is reached by 4-5 days of treatment with the drug (with the administration of 1 time / day).
    The introduction of a shock dose (on the first day), which is 2 times greater than the usual daily dose, makes it possible to achieve a level corresponding to 90% of the equilibrium concentration by the second day. The apparent volume of distribution approximates the fluid content in the body. Binding to plasma proteins - 11-12%.
    Fluconazole well penetrates into all body fluids. Concentrations of the drug in saliva and sputum are similar to those in plasma. In patients with fungal meningitis, the fluconazole content in the cerebrospinal fluid reaches 80% of its plasma level.
    In the stratum corneum, the epidermis, the dermis and the sweat fluid, high concentrations are reached that exceed the serum levels.
    Fluconazole is excreted mainly by the kidneys; approximately 80% of the administered dose is excreted in the urine unchanged. The clearance of fluconazole is proportional to the creatinine clearance.Metabolites of fluconazole in peripheral blood were not detected.

    Indications:
    - cryptococcosis, including cryptococcal meningitis and other localizations of this infection (including lungs, skin), both in patients with normal immune response, and in patients with different forms of immunosuppression (including AIDS patients, during transplantation bodies); the drug can be used to prevent cryptococcal infection in AIDS patients;
    - Genitalized candidiasis, including candidemia,
    disseminated candidiasis and other forms of invasive candidiasis infections (peritoneal, endocardial, eye, respiratory and urinary tract infections). Treatment can be performed in patients with malignant neoplasms, in intensive care units, in patients undergoing cytostatic or immunosuppressive therapy, and
    also in the presence of other factors predisposing to the development of candidiasis;
    -candidosis of mucous membranes, incl. oral cavity and pharynx (including atrophic candidiasis of the oral cavity, associated with the wearing of dentures), esophagus, non-invasive bronchopulmonary candidiasis, candiduria, candidiasis of the skin; prevention of recurrence of oropharyngeal candidiasis in AIDS patients;
    -genital candidiasis: vaginal candidiasis (acute and
    chronic recurrent), preventive use to reduce the frequency of recurrences of vaginal candidiasis (3 or more episodes per year); Candidiasis balanitis;
    -prophylaxis of fungal infections in patients with malignant neoplasms that are predisposed to such infections as a result of chemotherapy with cytostatics or radiation therapy;
    - mikozy skin, including mycosis of the feet, body, inguinal area; pityriasis lichen, onychomycosis; candidiasis of the skin;
    - Deep endemic mycoses, including coccidiomycosis, paracoccidiomycosis, sporotrichosis and histoplasmosis in patients with normal immunity.

    Contraindications:
    - simultaneous reception of terfenadine or astemizole and other drugs that extend the QT interval;
    -increased sensitivity to the drug or similar in structure to azole compounds;
    -childhood.

    Carefully:
    Hepatic and / or renal failure, concomitant administration of potentially hepatotoxic drugs, alcoholism, potentially pro-rhythmogenic conditions in patients with multiple risk factors (organic heart disease, electrolyte balance disorders, concurrent administration of medications that cause arrhythmias).

    Pregnancy and lactation:
    The use of the drug in pregnant women is not advisable, except for severe or life-threatening forms of fungal infections, if the expected effect exceeds the possible risk to the fetus.
    Fluconazole is found in breast milk in the same concentration as in plasma, so its use during lactation is not recommended.

    Dosing and Administration:
    Inside.
    With oropharyngeal candidiasis, the drug is usually prescribed for 150 mg 1 time / day; the duration of treatment is 7-14 days. If necessary, in patients with a marked decrease in immunity, treatment may be longer.
    For other candidiasis localizations (with the exception of genital candidiasis), for example, with esophagitis, noninvasive bronchopulmonary disease, candiduria, candidiasis of the skin and mucous membranes, etc., the effective dose is usually 150 mg / day with a treatment duration of 14-30 days. To prevent the recurrence of oropharyngeal candidiasis in AIDS patients after completing the full course of primary therapy, the drug can be prescribed 150 mg once a week.
    With vaginal candidiasis fluconazole taken once inside the dose of 150 mg.To reduce the frequency of recurrences of vaginal candidiasis, the drug can be used at a dose of 150 mg once a month. The duration of therapy is determined individually; it varies from 4 to 12 months. Some patients may need more frequent use.
    With balanitis caused by Candida, fluconazole appoint a single dose of 150 mg orally.
    With mycosis of the skin, including mycosis of the feet, skin of the inguinal area, and skin candidiasis, the recommended dose is 150 mg once a week. Duration of therapy in usual cases is 2-4 weeks, however, with foot mycoses, longer therapy (up to 6 weeks) may be required.
    With pityriasis - 300 mg (2 capsules) once a week for 2 weeks, some patients require a third dose of 300 mg per week, while in some cases it is sufficient to receive 300 mg once;
    With onychomycosis, the recommended dose is 150 mg once a week. Treatment should continue until the replacement of the infected nail (growth of uninfected nail). For the repeated growth of the nails on the fingers and toes normally takes 3-6 months. and 6-12 months. respectively.
    With systemic candidiasis and cryptococcal meningitis: an initial dose of 300 to 450 mg, then 150 to 300 mg daily, the duration of therapy depends on the clinical effect of the drug.
    In elderly patients in the absence of violations of kidney function should follow the usual dosage regimen. Patients with renal insufficiency (creatinine clearance less than 50 ml / min) dosage regimen should be adjusted as indicated below.
    Use of the drug in patients with impaired renal function.
    Fluconazole is excreted mainly with urine in unchanged form. With a single admission, a dose change is not required. When re-administering the drug to patients with impaired renal function, if creatinine clearance (CK) is more than 50 ml / min, the usual dose of the drug (100% of the recommended dose) is used. With SC from 11 to 50 ml / min, a dose equal to 50% of the recommended dose is applied. Patients regularly on dialysis, one dose of the drug is used after each session of hemodialysis.

    Side effects:
    On the part of the digestive system, changes in taste, vomiting, nausea, diarrhea, flatulence, abdominal pain, rarely - impaired liver function (jaundice, hepatitis, including fatal outcome, hepatonecrosis, hyperbilirubinemia, increased activity of alanine aminotransferases, aspartate aminotransferases, increase in activity of alkaline phosphatase).
    From the cardiovascular system: enlargement
    duration of the Q-T interval, flicker, ventricular flutter.
    From the nervous system, headache, dizziness, rarely - convulsions.
    From the hematopoiesis: rarely - leukopenia, thrombocytopenia, neutropenia, agranulocytosis.
    Allergic reactions: skin rash, rarely - malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), anaphylactoid reactions.
    Other: rarely - renal dysfunction, alopecia, hypercholesterolemia, hypertriglyceridemia, hypokalemia.

    Overdose:
    Symptoms: hallucinations, paranoid behavior.
    Treatment: symptomatic, gastric lavage, forced diuresis. Hemodialysis within 3 hours reduces the plasma concentration by approximately 50%.

    Interaction:
    When using fluconazole with warfarin, prothrombin time increases (on average by 12%). In this regard, it is recommended to carefully monitor the prothrombin time in patients receiving the drug in combination with coumarin anticoagulants.
    Fluconazole increases the half-life of plasma from oral hypoglycemic agents - sulfonyl urea derivatives (chlorpropamide, glibenclamide, glipizide, tolbutamide) in healthy people.Joint use of fluconazole and oral hypoglycemic agents in diabetic patients is allowed, but the doctor should keep in mind the possibility of developing hypoglycemia.
    The simultaneous use of fluconazole and phenytoin can lead to an increase in the concentration of phenytoin in the plasma to a clinically significant degree. Therefore, when it is necessary to jointly use these drugs, it is necessary to monitor the concentrations of phenytoin with
    correction of its dose in order to maintain the level of the drug within the therapeutic interval.
    The combination with rifampicin leads to a 25% reduction in AUC and a 20% decrease in the half-life of fluconazole from the plasma. Therefore, patients receiving concomitantly rifampicin, it is advisable to increase the dose of fluconazole.
    Fluconazole can significantly increase the level of cyclosporine in the blood in patients with kidney transplantation or without renal dysfunction (monitoring the concentration of cyclosporine and the level of creatinine in the blood).
    Patients who receive high doses of theophylline or who are likely to develop theophylline intoxication,should be monitored for the early detection of symptoms of an overdose of theophylline, as taking fluconazole leads to a decrease in the average clearance rate of theophylline from the plasma.
    With the simultaneous use of fluconazole and terfenadine, cisapride, cases of unwanted reactions from the heart, including paroxysms of ventricular tachycardia (torsades de points), are described.
    Simultaneous use of fluconazole and hydrochlorothiazide can lead to an increase in the concentration of fluconazole in plasma by 40%.
    There have been reports of an interaction between fluconazole and rifabutin, accompanied by an increase in serum levels of the latter. With the simultaneous use of fluconazole and rifabutin, cases of uveitis are described. It is necessary to carefully observe patients who simultaneously receive rifabutin and fluconazole.
    In patients receiving a combination of fluconazole and zidovudine, an increase in the concentration of zidovudine is observed, which is caused by a decrease in the conversion of the latter into its main metabolite, so an increase in the side effects of zidovudine should be expected.

    Special instructions:
    In rare cases, the use of fluconazole was accompanied by toxic changes in the liver, incl.with a fatal outcome, mainly in patients with serious concomitant diseases. In the case of hepatotoxic effects associated with fluconazole, there was no apparent dependence on the total daily dose, duration of therapy, sex, and age of the patient. The hepatotoxic effect of fluconazole was usually reversible; signs of it disappeared after discontinuation of therapy. If there are clinical signs of liver damage that may be associated with fluconazole, the drug should be discontinued.
    Patients with AIDS are more likely to develop severe skin reactions with many drugs. In those cases where the rash develops in patients with superficial fungal infection and it
    is regarded as definitely associated with fluconazole, the drug should be withdrawn. When rashes appear in patients with invasive / systemic fungal infections, they should be carefully monitored and canceled fluconazole when there are bullous changes or erythema multiforme.
    Caution should be exercised while taking fluconazole with cisapride, rifabutin or other drugs metabolized by the cytochrome P 450 system.

    Form release / dosage:
    150 mg capsules
    Packaging:
    1 capsule in a contour squeeze box made of PVC and aluminum foil, one outline package in a pack of cardboard together with instructions for use.

    Storage conditions:
    In a dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:
    2 years.
    Do not use after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:LSR-002239/07
    Date of registration:17.08.2007
    The owner of the registration certificate:Cadil Haltkar Co., Ltd.Cadil Haltkar Co., Ltd. India
    Manufacturer: & nbsp
    Information update date: & nbsp19.10.2015
    Illustrated instructions
      Instructions
      Up